Sunday 52-Week Lows

Chinese online travel agency Tuniu remains under pressure from a slow domestic travel recovery and tough competition from much larger booking platforms.

Recently public gaming and entertainment distributor has fallen more than 90% from its high on thin trading liquidity and heavy post-merger selling.

The microbiome drug developer trades near multi-year lows as the sector wrestles with funding strain and a long path to commercializing live-bacterial therapies.

Perimeter security sensor maker faces longer procurement cycles and pricing pressure as infrastructure and defense buyers tighten budgets.

The operator of Tim Hortons coffee shops in China keeps posting losses as it slows store growth amid soft Chinese consumer spending.

The digital media publisher stays in distress as print-to-digital ad declines and a heavy debt load weigh on the heavily diluted shares.

The lithium battery maker slipped to a 52-week low as cell oversupply and falling prices squeezed margins across the industry.

The closed-end fund that invests in CLO equity trades near its lows as worries about leveraged-loan credit weigh on its net asset value.

The carbon-recycling technology company sits near record lows on heavy cash burn and a long, uncertain road to scaling its gas-fermentation process.

The clinical-stage biotech working on a Parkinson's-related treatment trades near its lows, typical of a small developer awaiting pivotal trial data.

The Chinese children's educational-software provider stays pressured by tighter edtech regulation and slowing user growth.

The clinical-stage eye-disease drug developer trades near its lows as a small, pre-revenue biotech reliant on future trial readouts and fresh funding.

The maker of automated microbial-detection systems for drug manufacturing remains near lows on slow equipment adoption and continued losses.

The precision-oncology biotech swung to a quarterly loss as a one-time licensing payment rolled off, leaving it leaning on mid-stage lung-cancer and brain-tumor data.

The Chinese consumer-finance marketplace trades near lows on regulatory and credit risk despite a low headline valuation, a familiar China-ADR discount.

The Chinese mobile-software company stays depressed as its legacy app business shrinks and an AI pivot has yet to move results.

The clinical-stage immunology biotech trades near its lows as a small developer awaiting data on its lead intranasal antibody.

Monthly payouts from the natural-gas royalty trust have shrunk along with soft gas prices, pulling the units toward a 52-week low.

The opportunity-zone real estate vehicle trades near its lows as higher rates and a soft commercial-property market weigh on development values.

The maker of cryoablation tumor-treatment devices collapsed near multi-year lows on slow commercialization and repeated capital raises after an earlier FDA setback.

The bitcoin-mining-rig maker fell near a 52-week low after a wide quarterly loss and Q2 revenue guidance far below estimates, hurt by soft machine demand and crypto swings.

The biotech cratered after its lead asthma drug verekitug posted mixed Phase 2 data, with only the more frequent dose looking competitive, and analysts later flagged execution and financing risk.

The mall-based plush-toy retailer cut its full-year sales outlook after a soft quarter and a 26% drop in online demand, sending shares to a 52-week low amid a CEO change.

The Chinese used-car e-commerce platform stays near its lows as a thin-margin, cash-burning business in a weak Chinese auto market.

Shares crashed to a multi-year low after the eVTOL maker delivered just four aircraft in the quarter, far below expectations, with revenue collapsing and breakeven pushed out to 2029.

The middle-market lender drifted to a 52-week low amid broad pressure on business-development companies as investors fret over private-credit quality.

The non-operated Bakken oil producer eased toward a 52-week low as crude prices softened, though its high dividend keeps drawing income investors.

The sales-intelligence software firm sits near its lows after announcing a 20% workforce cut amid stalled growth and fears AI is eroding demand for its contact-data platform.

The nonprofit-fundraising software vendor fell to a 52-week low as slow organic growth and AI-disruption fears weighed on lower-growth vertical software.

The middle-market BDC hit a 52-week low after first-quarter credit markdowns produced a net loss and the base dividend was trimmed, though the shares still yield around 10%.

The non-operated oil and gas producer slid near a 52-week low as crude prices softened and a recently closed Canadian acquisition added share dilution, even with raised production guidance.

The auto-glass and collision-repair operator fell toward a 52-week low on softer same-store growth and cost inflation as insurers tightened repair spending.

Among the hardest-hit software stocks of 2026, Pega sits near a 52-week low after a Q1 revenue drop driven by lumpy term-license timing, even as its cloud recurring revenue kept growing.

The construction-management software maker hit a 52-week low in the broad software selloff, with a sluggish nonresidential building market and AI-disruption fears weighing on its growth premium.

Despite a Q1 earnings beat, the online pet retailer trimmed its full-year sales outlook, and shares sit near a 52-week low as stalled pet-household formation weighs on growth.

The fintech vendor to community banks fell to a fresh 52-week low despite beating quarterly estimates, as analysts trimmed price targets amid slowing growth and pressure on financial software.

The ad-tech firm has lost roughly three-quarters of its value over the past year on slowing revenue growth, a soft Q2 outlook, and heavy executive turnover including several CFO and revenue-chief exits.

The infrastructure-engineering software maker slid to a 52-week low in the broad software selloff despite beating quarterly estimates, as investors treated even AI-resilient names with caution.

Down nearly 60% from its high since a February bookings miss and weak 2026 outlook, with AI website-builder fears keeping the domain and hosting company near its lows despite strong cash flow.

The industrial-software maker hit a 52-week low in the software selloff; despite a Q2 beat, investors worry second-half growth leans on previously booked deferred revenue while new bookings look roughly flat.

The bank-technology vendor has trended lower for years and hit a fresh 52-week low after a soft second-quarter outlook overshadowed a first-quarter earnings beat, with analysts cutting targets.

Shares are down more than 60% from their high on fears that AI startups will disrupt its legal and tax research franchises, with recent in-line results and government-segment weakness adding pressure.

The RNAi drugmaker hit a fresh 52-week low as investors worried that growth of its flagship Amvuttra heart drug is slowing, reacting with a sell-the-news move to a $2 billion AI drug-discovery deal.

Caught in the software selloff on AI-disruption fears, shares hit a 52-week low despite 18% revenue growth, with guidance built around caution on a sales reorganization and a $3.6 billion acquisition.

The medical-device maker cut its 2026 growth outlook as its flagship Watchman heart implant slowed and rivals took share in pulsed-field ablation, pushing shares to a 52-week low.

Down over 40% in 2026 on AI-disruption fears for TurboTax and QuickBooks, with the May quarter pairing the slowest revenue growth since 2024 with a 17% workforce cut and up to $340 million in charges.

Shares hit a 52-week low ahead of Q2 earnings on fears that AI tools like Canva and Figma will erode demand for Photoshop, and a surprise CFO exit left the company without a permanent CEO or CFO.

One of the worst-performing large-cap software stocks of 2026, down about 37%, on fears AI will shrink seat-based software demand, even as its Agentforce AI platform grew more than 200%.